12-year positive survival data for BSD's hyperthermia therapy:
This article was originally published in Clinica
A 12-year follow-up study has shown positive survival rates for BSD Medical's precision-focused hyperthermia therapy device, BSD-2000, when used as an enhancement to radiotherapy. The 358-patient study assessed patients with locally-advanced pelvic tumours, and many had extremely poor prognoses. The follow-up found that patients who received radiation plus hyperthermia therapy had a survival rate of 37%, compared with 20% for those receiving radiation alone. Furthermore, the margin of increased survival rate of patients was similar at 12 years (an 85% increase) as at 3 years (an 89% increase). One of the primary concerns about new therapies is their durability, said Salt Lake City, Utah-based BSD. The findings were presented at the European Society for Hyperthermic Oncology, in Prague, Czech Republic, in June.